XOMA XOMA Corp Earnings per share for the last twelve months

XOMA Royalty relies on a robust network of licensing programs, which mitigates typical industry risks. The company's revenues are independent of economic cycles, as they are based on the demand for medications. The investment ecosystem of biotech assets forms a closed portfolio. Net income per share over 12 months demonstrates a growth trend, where the 1.57 metric serves as the target level.
Analytical breakdowns for XOMA Corp (XOMA)

The absence of capital expenditures in the XOMA Royalty (XOMA) royalty model allows for the direct conversion of biotech partners' successes into net income. This metric aggregates trailing twelve-month (TTM) earnings per share, isolating actual earnings from market noise, which enables the determination of the asset's fair value and prevents the purchase of an overpriced stock through the fundamental EPS TTM dynamics on GURU.Markets.